Companies: 10,795·Total market cap: $144.5T
Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

LCTXAMEXHealthcare● Active
$1.22
+$0.02(+1.67%)
Market Cap$302897428
P/E Ratio
52W High$2.09
52W Low$0.65

Lineage Cell Therapeutics, Inc.(LCTX)· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。

FMP · LCTX · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income
Breakdown2025-122024-122023-122022-122021-12
Revenue
Revenue$14.56M$9.50M$8.95M$14.70M$3.90M
Cost of Revenue$0.84M$0.33M$0.67M$0.73M$1.43M
Gross Profit$13.71M$9.16M$8.27M$13.97M$2.47M
Gross Margin %(computed)94.19%96.48%92.50%95.05%63.40%
Operating Expenses
R&D Expenses$17.73M$12.47M$15.71M$13.99M$33.91M
G&A Expenses$18.46M$18.17M$17.30M$22.51M$18.21M
Total Operating Expenses$35.49M$30.64M$33.01M$36.49M$51.68M
Operating Income($21.78M)($21.48M)($24.73M)($22.52M)($49.21M)
Operating Margin %(computed)-149.62%-226.11%-276.50%-153.17%
Interest Income$1.69M$1.72M$1.63M$0.83M$0.00M
Interest Expense$0.00M$0.00M$0.00M$0.00M$0.00M
Income Before Tax($68.65M)($18.58M)($23.28M)($25.81M)($43.27M)
Income Tax Expense($5.11M)$0.00M($1.80M)$0.54M$0.00M
Net Income($63.53M)($18.61M)($21.49M)($26.27M)($43.02M)
Net Margin %(computed)-436.47%-195.90%-240.20%-178.69%
Per Share & EBITDA
EPS (Basic)$-0.28$-0.09$-0.12$-0.15$-0.26
Wtd Avg Shares230.12M200.19M172.66M169.79M164.50M
EBITDA($21.08M)($20.87M)($24.04M)($21.79M)($48.34M)
EBITDA Margin %(computed)-144.82%-219.70%-268.76%-148.22%

数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · USD · M

深入了解Lineage Cell Therapeutics, Inc.

关于Lineage Cell Therapeutics, Inc.(LCTX)损益表

Lineage Cell Therapeutics, Inc.(LCTX)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,LCTX实现营收$0.01B,毛利润$0.01B(毛利率94.19%),净利润($0.06B)(净利率-436.47%)。

常见问题

LCTX · 4 问

Lineage Cell Therapeutics, Inc.(LCTX)2025财年营收为$0.01B,同比up53.2%。

LCTX revenueLCTX salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08